Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
bbotcs info on GNOM
I reckon the only negative is the large cash burn the company endures on a quarterly basis. They have attempted to take steps to correct this by laying off some employees and look into reviewing strategic alternatives. They still have a nice pile of cash & short term investments available. It is important to note that the company has two patents for the new technological breakthrough announced today. It appears that with this technology, their products will be more accurate than Illumina (ticker ILMN). It is worthy to note that Roche attempted to buyout ILMN earlier this year for $6.7 billion, yet ILMN's shareholders refused. Roche dropped its bid after this. "Roche’s refusal to pay a higher price may signal that investors aren’t sure Illumina will emerge as the leader in a race to introduce faster, cheaper, gene-sequencing instruments." Perhaps Roche would take a shot at purchasing GNOM on news of this new technology. The company is willing to sell after all as announced on their strategic alternatives press release in June. I am not sure if GNOM stock could go all the way back to its 52-week high, but I am hoping for at least $6-$8 in the short term.
Here is the article on the Roche bid:
http://www.bloomberg.com/news/2012-04-18/roche-drops-illumina-bid-on-concerns-of-flawed-technology.html
GNOM strategic alternatives PR on June 5th
Here is the press release from June 5th:
Complete Genomics Announces Restructuring Plan and Review of Strategic Alternatives
Company to Focus on Clinical Sequencing While Continuing to Deliver High-Quality Genomes to Researchers
GlobeNewswirePress Release: Complete Genomics, Inc. – Tue, Jun 5, 2012 6:48 AM EDT
MOUNTAIN VIEW, Calif., June 5, 2012 (GLOBE NEWSWIRE) -- Complete Genomics, Inc. (Nasdaq:GNOM - News), today announced that it is taking steps to reduce cash consumption and has engaged Jefferies & Company, Inc. to assist it in exploring strategic alternatives. The company also plans to focus on development of clinical applications for its whole human genome sequencing service, while continuing to provide high-quality genomes to research customers.
"Leading hospitals, health care systems and physicians are beginning to adopt whole human genome sequencing for clinical applications," said Dr. Clifford Reid, Complete's Chairman, President, and CEO. "Our industry-leading accuracy should position us well to capture this emerging opportunity."
Complete will maintain its current monthly capacity of approximately 1,000 genomes at 40x coverage or 500 genomes at 80x coverage. The company expects to delay capacity expansion beyond those numbers until demand for clinical-grade genomes supports expansion. The delay in expanding capacity is resulting in deferred capital expenditures and job cuts, primarily in field and factory headcount. Approximately 55 employee positions in Mountain View, California, and other U.S. locations will be eliminated.
This employee reduction is expected to be substantially completed during the current quarter ending June 30, 2012. Restructuring and related costs incurred with this plan are estimated at $1.5 million, most of which will be cash expenditures. These costs are comprised of one-time termination benefits for employees whose positions are being eliminated and should be recorded this quarter.
Complete Engages Jefferies & Company As Financial Advisor
Complete also announced that it has engaged Jefferies & Company, Inc. to act as financial advisor to the company and to assist in its review of strategic alternatives, which could include a merger, business combination, equity investment, or sale.
No decision has been made to enter into a transaction at this time, and there can be no assurance Complete will enter into a transaction in the future. The company does not plan to disclose or comment on developments regarding the strategic review process until it is complete or further disclosure is deemed appropriate.
GNOM amazing news!
Gobbled up a ton at $2.45. This company is on the auction block. I am guessing it could see $5 soon. Also has a Wall Street Journal article out on the news!
Complete Genomics Announces New Technology Developed to Set Standard for Clinical-Grade Genomes
Long Fragment Read Technology Described in Nature Paper Provides Much Higher Accuracy Sequencing
GlobeNewswirePress Release: Complete Genomics – 48 minutes ago
MOUNTAIN VIEW, Calif., July 11, 2012 (GLOBE NEWSWIRE) -- Complete Genomics, Inc. (GNOM) today announced that its Long Fragment Read (LFR) technology for whole genome sequencing dramatically improves accuracy, enables fully-phased genomes, and significantly reduces the amount of DNA required for testing. Complete's LFR technology should accelerate the use of whole genome sequencing by physicians to diagnose and treat their patients.
"We expect the introduction of this technological breakthrough to accelerate the move of whole genome sequencing into patient care, which in turn will begin to change the face of medicine," said Dr. Clifford Reid, Complete Genomics' chairman, president and CEO.
"The Nature paper by Peters et al. describes how our LFR technology uses 'barcoded' DNA to generate whole genome sequencing with approximately one error in 10 million base pairs, or just 600 errors in an entire human genome," said Dr. Rade Drmanac, the company's chief scientific officer and inventor of the LFR technology. "This represents a 10-fold increase in accuracy for Complete and is unmatched by any high-sensitivity method currently available."
Until now, determining whether two disease-associated variants were on the same or different parental chromosomes was either impossible or required expensive, low-throughput technologies -- an approach often infeasible in a clinical environment. Complete's new LFR technology not only enables an accurate identification of mutations, but includes phasing that shows which mutations are in fact together on the same parental chromosome. Through phasing, a physician can determine whether a patient with two pathogenic variants in a gene including its regulatory regions is affected or merely a carrier of the trait. In addition, Complete's LFR technology provides, for the first time, accurate whole-genome sequencing from as few as 10 to 20 cells (only 100 picograms of DNA), making it an ideal choice for small sample clinical sequencing applications including circulating tumor cells, fine needle aspirations, and pre-implantation genetic diagnostics.
"In the not-too-distant future, failure to use phasing when providing genomic diagnoses in patient care will be seen as unacceptably inaccurate," said Dr. George Church, professor of genetics at Harvard Medical School and director of PersonalGenomes.org. "I also suspect that LFR will reveal surprising things we didn't know were missing because we didn't have a tool to see them."
The U.S. Patent and Trademark Office has already issued Complete Genomics two separate patents on LFR technology, and additional patent applications, including miniaturization using nanodrops, are pending. Complete Genomics plans to incorporate the new technology into its sequencing offerings in early 2013.
About Complete Genomics
Through its pioneering sequencing-as-a-service model, Complete Genomics provides the most accurate whole human genomes generally available today. The ease of use and power of Complete's advanced informatics and analysis systems provide genomic information needed to better understand the prevention, diagnosis, and treatment of diseases. Additional information can be found at http://www.completegenomics.com.
The Complete Genomics logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8216
Forward-Looking Statement
Certain statements in this press release, including the incorporation of LFR technology into genomic sequencing and the potential future impact of LFR technology on medical care, are forward-looking statements that are subject to risks and uncertainties. These forward-looking statements are based on management's current expectations, and actual results may differ materially from our expectations. The following factors, without limitation, could cause actual results to differ materially from those in our forward-looking statements: the timing of the company's incorporation of LFR technology into its sequencing offerings and the pace of acceptance of human genome sequencing into patient care. More information on risk factors that could affect our results can be found in our Annual Report on Form 10-K filed with the SEC on March 9, 2012, and our Quarterly Report on Form 10-Q filed with the SEC on May 9, 2012, including those risks listed in those filings under the heading "Risk Factors." We disclaim any obligation to update information contained in our forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
For more information, contact:
Waggener Edstrom Worldwide Healthcare
Lisa Osborne
Account Director
(202) 261-7806
lisao@waggeneredstrom.com
Question on BOLL
BOLL looks fantastic and all with regards to financials, low share count, thinly traded and geared for aggressive spikes... but it appears the last time they filed an audited financial with the SEC was back in 2001. Did anyone look into why they filed a 15-12G to deregister with the SEC? Has anyone called the company to see if they plan on upgrading to the OTCBB exchange from the pink sheets? I think if they went down this route, the stock would spike huge.
MCAP 34 cent cash dividend & clean shell
Only 5 million shares outstanding. I think this one may be able to pop to $1-- reverse merger may be in the works.
MCAP 34 cent dividend, clean shell & 5 mil OS!
MCAP stock is giving a 34 cent cash dividend and will be a clean shell. I believe a reverse merger may be on the way. Only 5 million shares outstanding. Latest PR says that currently the company does not have any material business operations after dividend! RM may be around the corner.
KIK anything new or interesting on your radar?
I am liking LVWD and GAMR. My favorite biotech pick is AMRN-- think it has potential to see $30 on an FDA approval and likely buyout.
Also holding my other wildcards EVTN, ASCQ, and AHAG.
Congratulations on PSGY KIK!
This must have been your trade of 2012. My average price was 23 cents, though I had no where near the amount of shares you did! I stopped accumulating at a round even 50k shares, though I am extremely pleased. I did not think the company would be able to achieve this stock price level until 2013 assuming the growth rate continued.
This was a spectacular trade!
MCAP 34 cent dividend announced!
The company sold all of their patents for $2.3 million per their website. They are giving a 34 cent cash dividend to shareholders, and it appears they may do something with the clean shell post dividend. The press release states the company "currently" does not conduct substantive business operations. Does anyone on this board own any? I have a ton that I purchased 4 years ago!
Mango Capital Declares a Thirty-Four Cent Dividend
PR NewswirePress Release: Mango Capital, Inc. – 50 minutes ago
Companies:
NEW YORK, June 26, 2012 /PRNewswire/ -- Mango Capital, Inc. (Other Over the Counter: MCAP) announced today that its Board of Directors declared a thirty-four cent ($0.34) dividend as the result of the sale of the patents held by MangoSoft Intellectual Property, Inc., a wholly owned subsidiary of Mango Capital, Inc. (See, press release dated May 31, 2012). The record date is July 3rd and the payment date will be on or about July 13th. To save costs and expenses, and maximize the dividend to shareholders, Mango Capital, Inc. also hired Registrar and Transfer Company ("R&T Co.") (http://www.rtco.com) as its new transfer agent. R&T Co. will be administering the dividend process on Mango Capital's behalf. In the event you will be a shareholder on the record date, to ensure timely delivery of your dividend without a tax-withholding being applied, for shares you hold of record (shares registered directly in your name on our stock records with our transfer agent), please ensure R&T Co. has your proper address and completed IRS W-9 Form. Copies of the forms needed are available on Mango's website, www.mangocap.com. For shares held in "street name" by a brokerage firm, there is no need to provide any information to R&T Co.
Following this dividend payment, Mango Capital, Inc. and its subsidiaries do not have material assets, and they currently do not conduct any substantive business operations.
db7 MCAP 34 cent dividend
Did you ever end up buying any shares on the cheap? The company just put out a press release announcing they are giving shareholders a 34 cent dividend after selling their patents. I wonder if they are liquidating the company completely or if they plan on doing something with the shell. The last sentence they "currently" do not conduct any substantive business operations.
I have a pretty hefty chunk of shares from 3-4 years ago!
Mango Capital Declares a Thirty-Four Cent Dividend
PR NewswirePress Release: Mango Capital, Inc. – 50 minutes ago
Companies:
NEW YORK, June 26, 2012 /PRNewswire/ -- Mango Capital, Inc. (Other Over the Counter: MCAP) announced today that its Board of Directors declared a thirty-four cent ($0.34) dividend as the result of the sale of the patents held by MangoSoft Intellectual Property, Inc., a wholly owned subsidiary of Mango Capital, Inc. (See, press release dated May 31, 2012). The record date is July 3rd and the payment date will be on or about July 13th. To save costs and expenses, and maximize the dividend to shareholders, Mango Capital, Inc. also hired Registrar and Transfer Company ("R&T Co.") (http://www.rtco.com) as its new transfer agent. R&T Co. will be administering the dividend process on Mango Capital's behalf. In the event you will be a shareholder on the record date, to ensure timely delivery of your dividend without a tax-withholding being applied, for shares you hold of record (shares registered directly in your name on our stock records with our transfer agent), please ensure R&T Co. has your proper address and completed IRS W-9 Form. Copies of the forms needed are available on Mango's website, www.mangocap.com. For shares held in "street name" by a brokerage firm, there is no need to provide any information to R&T Co.
Following this dividend payment, Mango Capital, Inc. and its subsidiaries do not have material assets, and they currently do not conduct any substantive business operations.
LVWD looks like a good one
Just coming out with a nice couple press releases in a row and earnings have been on the upswing-- balance sheet looks great with cash. The share structure looks nice. I gobbled up some shares of the last couple days and plan on adding more.
I am not sure if someone else on the motherboard posted about this one before you, but thanks for mentioning it.
The only downside I see they stopped reporting with the SEC back in 2008, and therefore now they are currently trading as a pink sheet. Have you had a chance to contact anyone at the company to see if they plan on being a reporting stock again? I put in a call with investor relations.
KIK any updates on PSGY?
They have been quiet as of late. I believe the 10-Q is due out this coming Tuesday, May 15th. The company normally provided preliminary guidance before the 10-Q was filed. It appears they have deviated from this... what are your thoughts?
PSGY I agree
I like this one long term. I have continued accumulating shares... I hope we receive a strong Q1 number from the company soon. They typically issue a press release with preliminary guidance. Looks like the 1 cent per share dividend will be ongoing annually.
Expecting a PSGY PR soon
Based on history, I expect PSGY to come out with their preliminary estimates for Q1 this coming week. Hopefully, they deliver. I may add on strong numbers. We have been stuck in this 40-50 cent range for some time, and I reckon a breakout is due if Q1 numbers and or/guidance is strong.
ETMM huge seller taken out! We rock higher!
Look for a breakout end of day-- pushing past 4 pennies
ETMM needs to collapse!
Once enough shares are thrown at ETMM, we explode higher.
Gonna have another EOD run I am guessing
The last couple days of trading have seen a vicious end of day run. I expect the same today, and hopefully a gapper on Monday. It would be nice to have a PR about the majority stake, or some article interviewing our new billionaire stakeholder.
NEOM Billionaire acquires 26% stake
Dr. Patrick Soon-Shiong, the founder of Abraxis and multi-billionaire (I believe the 60th richest man in the world), purchased 113,494,743 shares, or 26%, in the open market at an average price of .0441 in NEOM. I think this stock is going a lot higher. This is being pumped by everybody. I accumulated a lot of shares in the 3.3 cent range today.
In June 2011, it looks like this stock got as high as 23 cents a share. On this material news, I could forecast this happening again....
VLXC very strange
I tried to place an order online. It would not let me. I called my broker (Etrade) and they told me they are not accepting any orders for the stock even though volume for the stock continued to trickle in throughout the rest of the day. My friend who has a broker through Ameritrade experienced the same thing. I saw volume continuing to trickle in up through the close. This is rather aggravating. Did anyone have a chance to buy more or sell any of their shares? I will be rather sad if this gaps open way higher. Any idea if this award is capable of being delivered?
FSII runner on EPS beat & guidance
Revenue of $38.5 million and EPS of .09 for quarter versus $32.09 million and .05 projected by analysts. Guides next quarter significantly higher at $50 million and EPS of .18-.23 versus analysts predictions of $36.34 and EPS of .13. Already seeing a nice bounce in after hours on huge volume---trading at around $5.05. There are over 3 million shares short.
10bagger re: EVTN
This stock trades on air. One really positive PR on a large order or a sexy 10-q quarterly report, and I bet we see a 50-100% move in one day-- only 23 mil shares outstanding and a small float. Look at how low volume it took last time to push the stock to $1-- not much. Potential is huge. As long as the CEO meets his sales forecast for 2012, I envision this trading a lot higher throughout the year. Is there any reason to doubt him? It appears his prior year forecasts were pretty dang close.
CPTMatt re: PSGY
Nuclear products made up 620k out of the $4.2 million in sales for fiscal year 2011. I would not be too concerned, as the 10-k filed today mentioned they expect sales in this segment to be similar or modest growth from 2011. They are expecting their largest segment, radioactive isotope detectors (which made up $3.1 million out of the $4.2 million in sales) to continue experiencing rapid growth. I suggest you browse through the 10-k filing. They also mentioned based on future growth, they expect to continue paying a 1 cent dividend annually. Here is a link to the 10-k annual report:
http://google.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=8492505-838-109350&type=sect&TabIndex=2&companyid=738566&ppu=%252fdefault.aspx%253fsym%253dpsgy
PSGY annual report highlights & dividend!
PSGY filed their annual report, 10-k today. This is the first time I have seen the audited report come out before the due date, a very positive sign. One very nice thing to note from the 10-k is the company plans on paying a .01 cent dividend annually going forward based on future growth prospects!! Per the 10-k filing
"Dividends.
We have declared a cash dividend of $.01 on our common stock. Based on future growth, we intend to continue declaring dividends of a minimum $.01 per annum."
Also, it appears the companies largest percentage of revenue comes from radioactive isotope identifies, which made up $3.1 million of the $4.2 million of sales. The company notes that it expects the rapid growth to continue in this segment, as well as continued growth in x-ray detectors. Per the 10-k filing,
"Our Business Growth
For the 12 month period ending December 31, 2011 our sales increased to $4,157,675 from $2,565,512. With the increased sales, our Net Profit was $495,599 compared to a Net Profit of $44,700 for the same 12 month period in 2010. Our Radioactive Isotope Identifiers had the biggest sales volume of all product categories with the sales of $3,078,159, and the second biggest category is the Nuclear products with the sale of $622,424 for the 12 month period. The third largest sales category is X-ray Detectors. The largest growth for the 12 month period was in Radioactive Isotope Identifiers, where the sales grew to $3,078,159 from $1,294,504 which represents 138% growth. This was due to enhanced sales distribution as well as introducing the new and more competitive products and applications to the market, as well as expanding more aggressively into the new geographical markets such as China.
The Company expects the growth to continue in the year 2012. Most of the growth will come from Radioactive Isotope Identifier products. We also expect X-Ray Detectors to generate a reasonable amount of growth in Sales. We expect the Nuclear Products to generate a moderate growth or remain at the same level as year 2011. "
I think the stock will start breaking out past the 50 cent level soon. A strong forecast for FY2012 should propel this stock higher. It also appears to me that they are a potential buyout target, with OY Chemec Espoo Finland Company owning almost 22% of all shares.
More juicy info related to future growth plans straight from the 10-k filing:
"Future Growth Plans and Markets
By purchasing complex technology developed over the last thirty years, we believe we have the capability to enter into a growing marketplace in the Homeland Security as well as overall detector field. We are hopeful we can provide improved focus to products and related technology that was not receiving the attention or funding it required while operating as a subsidiary of a large multinational company whose primary focus was moving in another direction. We have spent the last four years improving upon the technology acquired; further developing new innovative products and refocusing our strategy on the growing need for sophisticated and dedicated detection units and components. We are hopeful this focus will allow us to be at the forefront of increased spending on detection devices for the commercial and homeland security markets. Three markets we see as new uses for our products are in the homeland security marketplace where there is a continuous need for dangerous radioactive and nuclear material to be identified by several authorities; Nuclear power plant market and in the "quality control" area where testing equipment has become a crucial part of the manufacturing process.
Although security issues have been around before, there is a new and on-going need to be able to detect various radioactive isotopes in different security and environmental settings. This marketplace is expanding throughout the world. This need is being created not only from the fear of terrorism but also from the expansion of the use of various chemicals and radiation in the manufacturing environments and the need to assure radiation is not being released inadvertently into the environment. We have created several detectors and related components aimed directly at this need and will continue to work on the development of even more sophisticated devices for this expanding market.
The past Nuclear Power plant crisis in Japan has resulted in an increased level of interest in radiation detection related to the Nuclear Power plants. Due to the leaked isotopes, which are extremely dangerous for people living close to those areas, coming from Nuclear Power plants we see that our products have a potential to detect such isotopes; whether RIIDs , Fixed Area Monitors or High Purity Germanium based systems are being deployed in such circumstances. This market has been there for decades but not until last year has it become more critical due to serious recent Nuclear Power plant problems in Japan. Therefore we believe that this market will provide company real growth opportunities.
As manufacturers continue to create more complex products relying heavily on automation, we believe that they will continue to require products such as detectors and testing equipment capable of evaluating the quality of the products produced. We have seen this in the silicon wafer fabrication process where we currently provide component parts to help detect any defects in the chips. Another new application for us is the detection of radioactive raw material in a manufacturing process within a marble industry or steel industry. We believe these "quality control" products will continue to see increasing demand and the use of our products will expand.
Princeton's plan of operation going forward consists of a two tier approach including a marketing strategy and a sales strategy.
Our marketing strategy includes a number of defined processes, and will leverage existing marketing plans from Princeton and affiliate companies. Campaigns run on a regular basis will include a tradeshow schedule, direct mail, email, telemarketing and direct sales calls, user groups and radiation detection workshops. Furthermore, our marketing efforts will also introduce a one-to-one customer driven outline to address the network and support needs of each customer.
We intend to prioritize customer service and make it a key component of our marketing programs. We believe that providing our customers with what they want, when and how they want it, has been fundamental in the development of our reputations in the industry.
Because we want to develop close working relationships with our customers, we want to establish accounts in as personable a way as possible. It is for this reason that we will overwhelmingly emphasize in-person sales visits.
We will closely integrate all of our marketing and sales efforts to project a consistent image of our company and a consistent positioning of our products and services. Furthermore, to support our marketing initiatives and effect legislative actions, we plan to participate in several Washington, D.C. based DHS (Department of Homeland Security) events directly or indirectly via our partners and consultants, and utilize a lobbyist in Washington, D.C. with contacts in the security business.
Our sales strategy includes focusing initial efforts on the top level decision maker or influencer at each targeted government agency. Princeton will also work with DHS to determine which government agencies are appropriate for immediate deployment of advanced technology. "
ToyotaMR2s follow up
Are you a millionaire now? Haha.
I have an interesting shell that you might consider investing in. The ticker is AHAG- Alpha Group Technologies. The company only has 7.1 million shares outstanding. They filed a 15-12G in 2008, which I believe will put them in place for an eventual reverse merger. The two majority shareholders in the company Marshal Butler and Lawrence Butler are big names. Lawrence Butler founded Steel Partners hedge fund with Warren Lichenstein, a big name that has appeared to be behind a couple huge reverse mergers. I have additional details of a potential reverse merger on the AHAG message board. I think one day this may be the one to pop.
Here are the largest shareholders:
Lawrence Butler 1,720,622 22.6%
Marshall D. Butler 1,007,342 13.9%
Dot. Com Partners, L.P. 695,038 9.8%
Dimensional Fund Advisors Inc. 356,716 5.0%
Here are details on the two largest holders:
http://people.forbes.com/profile/marshall-butler/135203
http://investing.businessweek.com/research/stocks/people/person.asp?personId=306724&ticker=AHAG:US
ToyotaMR2 Question for you regarding FNCX
I noticed that you first posted about this stock in November 2010 well before the reverse merger occurred. Did you actually own any shares before the merger happened? Did you get to keep all those shares you purchased before the 8-k came out?
Thoughts on filing
Perhaps they are planning on going private or perhaps Anthony Hayes is planning on a tender offer. This stock is mainly owned by three individuals and there is barely any trading volume.
PSGY iRobot (IRBT) using PSGY detectors
I don't see this press release out, but it is posted on PSGY's website: http://www.pgt.com/item/seaglider-uuv-pgt-scintillator-detector.html
http://www.pgt.com/images/stories/os_2012_poster.pdf
iRobot (ticker: IRBT) releases new product poster on their Seaglider UUV incorporating PGT's Scintillator Detector
News, March 07 2012,
iRobot new product
iRobot new product poster highlights their Seaglider, a long-range, high-endurance Unmanned Underwater Vehicle (UVV) for surveillance and monitoring missions that covers thousands of kilometers, for months at a time and at the fraction of the cost of traditional equipment.
iRobot partnered with Princeton Gamma-Tech Instruments to integrate into their Seaglider an underwater scintillation detector to locate radioactive debris. The poster shows data collected in the seas off Japan around the damaged Fukushima nuclear reactors, looking for I-131, Cs-134 and Cs-137. Mapping a larger area allows for more targeted survey points and increased data resolution.
JVA yeehaw
Rockin higher! I am up way too much on this one. I sold 75% of my position in the 12.60s.... cannot be a pig!
PSGY iRobot using PSGY detectors
I don't see this press release out, but it is posted on PSGY's website: http://www.pgt.com/item/seaglider-uuv-pgt-scintillator-detector.html
iRobot (ticker: IRBT) releases new product poster on their Seaglider UUV incorporating PGT's Scintillator Detector
News, March 07 2012,
iRobot new product
iRobot new product poster highlights their Seaglider, a long-range, high-endurance Unmanned Underwater Vehicle (UVV) for surveillance and monitoring missions that covers thousands of kilometers, for months at a time and at the fraction of the cost of traditional equipment.
iRobot partnered with Princeton Gamma-Tech Instruments to integrate into their Seaglider an underwater scintillation detector to locate radioactive debris. The poster shows data collected in the seas off Japan around the damaged Fukushima nuclear reactors, looking for I-131, Cs-134 and Cs-137. Mapping a larger area allows for more targeted survey points and increased data resolution.
10bagger re: EVTN
Damn brother. You are creating the market! Probably about a third of all the volume on EVTN is you! Hahaha. Are you holding any shares for the long-term? or you just keep flipping? We probably could see more material upside if you lay off the ask! ;)
I think this one has potential to hit a dolla again-- if revenue growth continues at this rapid pace and traders enter, I envision by year end this could be at least a 5-bagger. I own 60k shares at an average .1231.
JVA on fire- expecting Monday gap!
This may pull a BVSN. The share count/tiny is float. It has been pumped before. I am hoping for a gapper Monday morning--maybe $1+ at the open.
PSGY (.45) to expand distribution PR out
It appears PSGY signed a distribution agreement with Rae Systems, Inc-- a company that was bought out for around $100 million in June 2011. It is great that they made a committment to purchase a certain amount of PSGY's products each year. This provides the company with more visibility...order backlog+commitments total $2 million-- I am guessing the company should be able to meet their revenue goal of $6-$10 million this year.
Princeton Security Technologies, Inc. (PSGY) to Expand Its Distribution for Radiation Identifier Products
MarketwirePress Release: Princeton Security Technologies, Inc. – 35 minutes ago
PRINCETON, NJ--(Marketwire -03/07/12)- Princeton Gamma-Tech Instruments, a wholly owned subsidiary of Princeton Security Technologies, Inc. (OTC.BB: PSGY.OB - News), announced that it had signed a distribution agreement for its identifier products with Rae Systems Inc., a San Jose, California based company which specializes in chemical and radiation detection products. Rae Systems made a sizeable commitment to purchase minimum quantities per year and will add more geographical depth to Princeton's product distribution.
Recently, Princeton Gamma-Tech Instruments received sizeable orders from its Chinese distributors for its Radiation Identifier Products. Therefore Company's existing order backlog and 2012 commitments is currently approx. $2 million, where all the product deliveries are expected to take place between March and the year end.
About Princeton Security Technologies, Inc.:
Princeton Security Technologies, through its wholly owned subsidiary, Princeton Gamma-Tech Instruments, Inc (PGT), is a leading developer of Radiation Isotope Identifiers, Radiation Area Monitors and High Purity Germanium detector technology for Nuclear Power plants, Homeland Security, National Research Laboratories, and overseas nuclear safety agencies.
Further information regarding Princeton Security Technologies can be found at www.PGT.com
Contact:
Investor
Trupti Mehta
Email Contact
(609)924-7310
KIK thoughts on CVV?
Have any thoughts on CVV going into earnings? I think they are due today after the bell. It appears to me that a beat may be in order. The only analyst that covers it has a $18 price target. The share count and float is tiny. Considering buying a little going into the earnings...
Do you own any shares?
db7
how many shares you holding bud? I got 12.5k
db7 there are two MMs under $2
I see NITE at .70 and UBSS at .80... then four MMs lined up at $2. This one has a tiny float. All we need is one piece of good news and I reckon we break $1.
EVTN on the Shale Gas Water Management webpage
Listed as an exhibitor, just as mentioned by EVTN latest PR.
http://www.shale-gas-water-management-2012.com/10/exhibitors/
Added more EVTN
Up to 55k shares now. I like this one a lot. If the CEO could deliver on projected sales growth for 2012, I foresee profitability and perhaps a stock price north of 50 cents. I never received your email about PSGY.
ATPG looks great
I bought in last week. I think this one has a lot more room to go higher. That well at 7k BOEPD is spectacular and should allow them to easily cover their debt payments.
ASCQ (.42) completes merger agreement with Andover Games
The float on this stock is tiny! Management has agreed to lock up their shares for a 12-month period. Volume is kicking through today on a Friday. Looks like a private placement was done at 50 cents, which is above the current stock price. With the recent news and tiny share count/potential of this, I believe this could go to $1 by next week. We will see. Very little shares are tradable....
Ascend Acquisition Corp. Completes Merger with Mobile Gaming Company Andover Games
9:24 AM ET 3/2/12 | BusinessWire
Ascend Acquisition Corp. (OTC BB: ASCQ) ("Ascend Acquisition" or the "Company") announced that it has completed its previously announced merger with San Francisco-based mobile gaming company, Andover Games, LLC ("Andover Games"). As a result of the transaction, Andover Games has become a wholly owned subsidiary of Ascend Acquisition and will continue as its operating subsidiary.
Under the terms of the merger agreement, simultaneously with the closing of the merger, Ascend Acquisition completed a private placement of 4 million shares of common stock at $0.50 per share, resulting in $2 million in gross proceeds to the Company. The proceeds will be used for the completion and roll-out of multiple mobile games under direct and indirect development at Andover Games, human capital development, strategic acquisitions, and working capital. The Company will register the resale of the shares sold in the private placement on a registration statement on Form S-1 to be filed with the Securities and Exchange Commission ("SEC") in March 2012.
In connection with the merger, the members of Andover Games have exchanged their equity interests in Andover Games for an aggregate of 38,195,025 shares of Ascend Acquisition. These shares are subject to a 12-month contractual lock up and then will be subject to further regulatory restrictions. Audited financial statements for the period ending December 31, 2011 for Andover Games will be filed by the Company in a Current Report on Form 8-K with the SEC within four business days from the closing.
As a result of this transaction, there are now 50,926,700 shares outstanding of Ascend Acquisition. The number of shares outstanding of Ascend Acquisition will increase depending on the amount of proceeds it raises in the second portion of the private placement which may raise up to an additional $2 million of gross proceeds to the Company within the next 30 days pursuant to the merger agreement.
"We are excited about becoming a public company with this merger with Ascend Acquisition," said Craig dos Santos, President and CEO of Andover Games. "We believe the ability to use public stock and stock options to attract the very best talent in the mobile gaming industry provides us with a major advantage over our privately held competition. It also makes it possible for us to make both strategic acquisitions of competitors and to make publishing deals with smaller firms in our industry," said Mr. dos Santos.
"We are pleased that we are welcoming several strategic investors in the media, entertainment and investment communities to our private stock offering who will add significant value to Andover Games in the months ahead," said Jonathan Ledecky, Chairman of Ascend Acquisition. "These 'value-added' investors believe that the talented personnel at Andover Games can successfully navigate the high growth environment prevalent in mobile gaming today," said Ledecky.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Ascend Acquisition. The securities offered and/or sold in Ascend Acquisition's private placement have not been registered under the Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration under the Securities Act of 1933, as amended, and applicable state securities laws.
MCAP potential licensing agreement or patent sale
SEC filing just came out a couple days ago. Apparently, the new shareholder Anthony Hates is a lawyer. He purchased a huge 26.3% stake in the company because he was interested in their patents. According to the SEC filing, Anthony Hates will work for MCAP for only $1 a year. He will review the patents, and work on completing licensing agreements for them or selling the patents outright. His law firm will only be paid if the company either wins a lawsuit, enters into a licensing agreement, or sells the patents. The split is 75% of net proceeds going to MCAP and the remaining 25% going to the law firm Atwater Partners of Texas LLC. One quick google search on Atwater Partners shows they have sued several huge technology firms, including Ericsson, Nokia, AT&T, and Alcatel-Lucent. Very very interesting. With one major licensing agreement or patent sale, this could absolutely skyrocket...only 5.6 million shares outstanding. A shame the spread is so ridiculous right now, 3.7 cent bid and 1 dollar ask.
Back in the day this company sued Oracle for $500 million. They also sued Ebay and Skype, and settled with them for $2.3 million a few years ago. Will be interesting to see what comes of this...
http://google.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=8410759-9614-30590&type=sect&TabIndex=2&companyid=4420&ppu=%252fdefault.aspx%253fsym%253dmcap